Medicine and Dentistry
Breast Cancer
100%
Head and Neck Squamous Cell Carcinoma
96%
Neoplasm
95%
Metastatic Breast Cancer
61%
Immune Checkpoint Inhibitor
57%
Overall Survival
56%
Progression Free Survival
47%
Capecitabine
42%
Biological Marker
36%
Fluorouracil
35%
Palbociclib
33%
Metastatic Carcinoma
33%
Triple Negative Breast Cancer
33%
Hazard Ratio
31%
Hormone Receptor
30%
Phase II Trials
30%
Cisplatin
30%
Cancer Cell
28%
Induction Chemotherapy
26%
Neck
24%
Combination Therapy
23%
Gamma Urogastrone
23%
Nintedanib
21%
Epidermal Growth Factor Receptor 2
21%
Hormone Therapy
21%
Premenopause
20%
Neoadjuvant Chemotherapy
20%
Ascorbic Acid
19%
Gefitinib
19%
Stomach Adenocarcinoma
19%
Germinoma
19%
Biliary Tract Cancer
19%
Endodermal Sinus Tumor
19%
Squamous Cell Carcinoma
19%
Breast Carcinoma
19%
Non Small Cell Lung Cancer
19%
Organizing Pneumonia
19%
Spindle Cell Sarcoma
19%
Rheumatoid Arthritis
19%
Lymph Node Metastasis
19%
Supraclavicular Lymph Node
19%
Wernicke's Encephalopathy
19%
Salivary Gland Cancer
19%
Etanercept
19%
Retrospective Cohort Study
19%
Hematopoietic Stem Cell Transplantation
19%
Inflammatory Arthritis
19%
Exemestane
19%
Patient Participation
19%
Health Care Cost
19%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
83%
Neoplasm
78%
Head and Neck Squamous Cell Carcinoma
77%
Breast Cancer
67%
Metastatic Breast Cancer
61%
Progression Free Survival
51%
Capecitabine
49%
Phase II Trials
40%
Immune Checkpoint Inhibitor
38%
Monotherapy
38%
Hormone Receptor
36%
Triple Negative Breast Cancer
34%
Fluorouracil
32%
Tamoxifen
31%
Biological Marker
30%
Catenin
28%
Imatinib
28%
Ramucirumab
28%
Paclitaxel
28%
Palbociclib
24%
Survival Rate
23%
Nintedanib
21%
Malignant Neoplasm
19%
Hepatotoxicity
19%
Cohort Study
19%
Transdermal
19%
Gefitinib
19%
Non Small Cell Lung Cancer
19%
Duragesic
19%
Chronic Myeloid Leukemia
19%
Biliary Tract Cancer
19%
Tolerability
19%
Erlotinib
19%
Wernicke's Encephalopathy
19%
Gemcitabine
19%
Rheumatoid Arthritis
19%
Etanercept
19%
Inflammatory Arthritis
19%
Salivary Gland Cancer
19%
Atezolizumab
19%
Neutropenia
15%
Disease Free Survival
15%
Cisplatin
15%
Protein Tyrosine Kinase Inhibitor
12%
Adenoid Cystic Carcinoma
12%
Gamma Urogastrone
12%
Primary Tumor
12%
Trastuzumab
11%
Eribulin
11%
Nivolumab
11%
Biochemistry, Genetics and Molecular Biology
Circulating Tumor DNA
38%
Cancer Cell
28%
Catenin
28%
Immune Checkpoints
28%
Progression Free Survival
26%
CD44
21%
Overall Survival
20%
Gefitinib
19%
Erlotinib
19%
Blood Plasma
19%
Prevalence
19%
Phase II Trials
19%
Capecitabine
19%
Protein Kinase B
14%
Gene Expression Profiling
12%
Hormone Receptor
12%
Homologous Recombination
12%
Tumor Volume
10%
Epidermal Growth Factor Receptor
9%
Exon
9%
Genotyping
9%
TSC2
9%
Myeloid
9%
Fluorouracil
9%
MEK Inhibitor
9%
Imatinib
9%
MSH6
9%
ARID1A
9%
MLH1
9%
Tumor Gene
9%
Genetic Counseling
9%
DNA Damage Response
9%
Mutation Rate
9%
GATA3
9%
Tumor-Infiltrating Lymphocytes
9%
Prospective Study
9%
Germline
9%
Germ Cell
9%
BRCA1
9%
Cell Cycle
8%
Stem Cell
7%
Gene Frequency
7%
BRCA2
6%
Receptor Tyrosine Kinase Inhibitors
6%
